Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
$8.03
-0.2%
$8.02
$6.10
$28.67
$556.11M1.6396,082 shs133,334 shs
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
$4.28
-1.8%
$3.50
$2.49
$8.54
$397.39M2.27837,963 shs2.12 million shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$9.28
-0.2%
$9.17
$7.44
$10.90
$465.01M-0.1271,153 shs170,750 shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$7.70
+2.7%
$8.52
$7.10
$21.79
$292.24M0.04131,038 shs143,697 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-0.25%-5.64%-4.63%-29.06%-65.13%
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-1.83%-7.36%+12.04%+15.68%-42.78%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-0.22%-1.80%-4.82%+2.20%+11.27%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
+2.67%-6.55%-12.90%-35.94%-49.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
3.8334 of 5 stars
4.43.00.00.02.94.20.6
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
1.7519 of 5 stars
3.51.00.00.02.80.80.6
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.7326 of 5 stars
2.10.00.00.01.62.50.6
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
2.9973 of 5 stars
3.63.00.00.02.81.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
2.70
Moderate Buy$25.00211.33% Upside
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
3.00
Buy$18.83340.03% Upside
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.25
Hold$11.3322.13% Upside
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.25
Buy$25.67233.33% Upside

Current Analyst Ratings Breakdown

Latest BCYC, TBPH, TRDA, and CMPS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$12.00
5/20/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/13/2025
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/12/2025
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
5/5/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/1/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.00
4/9/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
$25.72M21.62N/AN/A$12.35 per share0.65
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$3.65 per shareN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$65.27M7.11N/AN/A$4.28 per share2.17
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$172.22M1.70N/AN/A$7.26 per share1.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-$180.66M-$3.14N/AN/AN/A-450.64%-27.35%-20.81%8/5/2025 (Estimated)
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$118.46M-$1.99N/AN/AN/AN/A-63.85%-51.97%8/7/2025 (Estimated)
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$55.19M-$1.18N/A26.51N/A-78.18%-24.79%-13.43%8/4/2025 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$6.68M$0.814.84N/AN/A25.53%16.11%10.39%8/12/2025 (Estimated)

Latest BCYC, TBPH, TRDA, and CMPS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$0.47-$0.44+$0.03-$0.24N/AN/A
5/8/2025Q1 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million
5/8/2025Q1 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million
5/1/2025Q1 2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
N/A
17.13
17.13
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
0.15
8.91
8.91
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
4.97
4.97
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
6.59
6.59

Institutional Ownership

CompanyInstitutional Ownership
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
86.15%
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
46.19%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
99.10%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%

Insider Ownership

CompanyInsider Ownership
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
22.90%
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
4.25%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
6.90%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
8.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
24069.25 million63.18 millionOptionable
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
12092.85 million65.51 millionOptionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
35950.00 million45.78 millionOptionable
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
11037.95 million34.58 millionOptionable

Recent News About These Companies

HC Wainwright Has Positive Forecast for TRDA Q2 Earnings
Q2 Earnings Forecast for TRDA Issued By HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicycle Therapeutics stock logo

Bicycle Therapeutics NASDAQ:BCYC

$8.03 -0.02 (-0.25%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$8.18 +0.15 (+1.87%)
As of 05/27/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

COMPASS Pathways stock logo

COMPASS Pathways NASDAQ:CMPS

$4.28 -0.08 (-1.83%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.37 +0.09 (+2.01%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$9.28 -0.02 (-0.22%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.28 0.00 (0.00%)
As of 05/27/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$7.70 +0.20 (+2.67%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.70 0.00 (-0.06%)
As of 05/27/2025 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.